# Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis

> **NCT06811025** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Beijing Chest Hospital** · enrollment: 24 (estimated)

## Conditions studied

- Tuberculosis
- Meningitis

## Interventions

- **DRUG:** Contezolid
- **DRUG:** Linezolid (LZD)

## Key facts

- **NCT ID:** NCT06811025
- **Lead sponsor:** Beijing Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-02-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06811025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06811025, "Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06811025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*